Straumann consensus picture on Tuesday, shares in the Swiss dental sector

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:22.

Straumann Holding AG (CH0012280076) opens this Tuesday with a stable presence on SIX Swiss Exchange in Zurich, where the shares remain a core component of the Swiss equity market. The stock is listed in the blue-chip SMI index and continues to attract international dental-sector investors.

What analysts say today

The current consensus view on Straumann is characterized by a majority of Buy and Outperform ratings from large international and Swiss research houses, reflecting confidence in the long-term growth of the dental implant and clear-aligner markets. Several major investment banks and research firms, including UBS, Credit Suisse, and Deutsche Bank, regularly publish assessments and model updates on the stock.

Across these houses, the average twelve-month price target is typically set at a premium to the prevailing share price, indicating expectations for continued earnings expansion, margin resilience, and solid cash generation in the specialist medical technology segment. Rating distributions frequently show a small minority of Hold recommendations and very few formal Sell calls, underlining a broadly constructive stance.

Consensus numbers and earnings focus

On the earnings side, analysts project mid to high single-digit organic revenue growth for Straumann over the coming years, supported by demographic trends, increasing dental awareness, and rising penetration of premium implant solutions. Forecasts for operating margins often remain robust, with expectations that management will defend profitability despite cost inflation and investment in innovation.

Consensus models also tend to assume continued investment in digital dentistry solutions, training, and emerging-market expansion, which together support medium-term growth in earnings per share. Many houses build in incremental contributions from clear-aligner offerings and value-oriented implant lines, while still seeing Straumann as predominantly a premium-positioned player in restorative dentistry.

The product behind the stock

Straumann generates most of its revenue with dental implant systems and related prosthetic components that are used by dentists and oral surgeons to replace missing teeth in a durable and aesthetic way. The portfolio also includes biomaterials such as bone grafting products, clear-aligner orthodontic solutions, and digital workflows that connect scanners, planning software, and chairside design.

Where the shares trade today

The Straumann shares (CH0012280076) trade on 2026-06-30, 09:22 on SIX Swiss Exchange in Zurich, with prices quoted in Swiss francs; live data on the latest trading price and market capitalization is available directly from the exchange and major financial data platforms.

This text is for information purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. All data are subject to change; investors should consult multiple sources and, where appropriate, a professional advisor before making decisions.